TapewireFind a company

person · Reporting owner

LaBarre Michael J.

Disclosed activity across 1 company

Tapewire entity
82745
SEC CIK
0001507174

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
HALOZYME THERAPEUTICS, INC.HALO · Entity 793SVP, CHIEF TECHNICAL OFFICERFebruary 25, 2025February 27, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

HALOZYME THERAPEUTICS, INC.

Report date February 25, 2025 · Filed February 27, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect173,756 Ending reported balance After 2025-02-27 transaction · row 6
6 source rows · reconciled sequence

Row 1 · 2025-02-25 · Sale · Disposed 9,300 · Balance 186,153

F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.

F2: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.54 to $58.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 2 · 2025-02-25 · Sale · Disposed 700 · Balance 185,453

F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.

F3: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.54 to $58.91. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 3 · 2025-02-26 · Sale · Disposed 9,400 · Balance 176,053

F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.

F4: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.62 to $58.61. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 4 · 2025-02-26 · Sale · Disposed 600 · Balance 175,453

F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.

F5: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.62 to $58.68. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 5 · 2025-02-27 · Sale · Disposed 1,597 · Balance 173,856

F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.

F6: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.71 to $58.66. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 6 · 2025-02-27 · Sale · Disposed 100 · Balance 173,756

F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.

F2: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.54 to $58.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.54 to $58.91. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.62 to $58.61. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F5: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.62 to $58.68. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F6: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.71 to $58.66. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 16, 2024 Filed Feb 20, 2024 23:59 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 4,264 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-004477 · form4-02202024_110252.xml · nonDerivative · entry 3

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 171,247

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 16, 2024 Filed Feb 20, 2024 23:59 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Tax withholdingCommon Stock 3,097 $36.10 $111,801.70
Disclosure

SEC source: 0001415889-24-004477 · form4-02202024_110252.xml · nonDerivative · entry 2

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 166,983

F1 · shares: The reported disposition of 3,097 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.

Read SEC document
February 16, 2024 Filed Feb 20, 2024 23:59 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 6,112 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-004477 · form4-02202024_110252.xml · nonDerivative · entry 1

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 170,080

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 15, 2024 Filed Feb 16, 2024 22:47 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionRestricted Stock Units · Derivative 3,386 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001415889-24-004187 · form4-02162024_100206.xml · derivative · entry 5

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,386

Underlying: Common Stock · 3,386 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.

F4 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.

Read SEC document
February 15, 2024 Filed Feb 16, 2024 22:47 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Tax withholdingCommon Stock 3,832 $35.91 $137,607.12
Disclosure

SEC source: 0001415889-24-004187 · form4-02162024_100206.xml · nonDerivative · entry 4

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 163,968

F3 · shares: The reported disposition of 3,832 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations.

Read SEC document
February 15, 2024 Filed Feb 16, 2024 22:47 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantCommon Stock 8,479 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-004187 · form4-02162024_100206.xml · nonDerivative · entry 3

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 167,800

F2 · security: This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer.

Read SEC document
February 15, 2024 Filed Feb 16, 2024 22:47 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Tax withholdingCommon Stock 1,208 $35.91 $43,379.28
Disclosure

SEC source: 0001415889-24-004187 · form4-02162024_100206.xml · nonDerivative · entry 2

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 159,321

F1 · shares: The reported disposition of 1,208 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations.

Read SEC document
February 15, 2024 Filed Feb 16, 2024 22:47 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 3,386 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-004187 · form4-02162024_100206.xml · nonDerivative · entry 1

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,529

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 10, 2024 Filed Feb 13, 2024 21:18 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionRestricted Stock Units · Derivative 8,133 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001415889-24-003529 · form4-02132024_090202.xml · derivative · entry 3

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,133 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.

F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.

Read SEC document
February 10, 2024 Filed Feb 13, 2024 21:18 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Tax withholdingCommon Stock 2,901 $35.49 $102,956.49
Disclosure

SEC source: 0001415889-24-003529 · form4-02132024_090202.xml · nonDerivative · entry 2

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 157,143

F1 · shares: The reported disposition of 2,901 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations.

Read SEC document
February 10, 2024 Filed Feb 13, 2024 21:18 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 8,133 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-003529 · form4-02132024_090202.xml · nonDerivative · entry 1

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,044

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 17, 2024 Filed Jan 18, 2024 21:07 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 10,000 $0.00 Strike: $12.07 $0.00
Disclosure

SEC source: 0001415889-24-001520 · form4-01182024_090126.xml · derivative · entry 6

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,885

Underlying: Common Stock · 10,000 shares

Expires 2027-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F3 · derivative.exercise_date: This option was granted on February 22, 2017 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
January 17, 2024 Filed Jan 18, 2024 21:07 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 10,000 $36.00 $360,000.00
Disclosure

SEC source: 0001415889-24-001520 · form4-01182024_090126.xml · nonDerivative · entry 4

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 151,911

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $36.00 to $36.01. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
January 17, 2024 Filed Jan 18, 2024 21:07 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 10,000 $12.07 $120,700.00
Disclosure

SEC source: 0001415889-24-001520 · form4-01182024_090126.xml · nonDerivative · entry 3

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 161,911

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

Read SEC document
January 16, 2024 Filed Jan 18, 2024 21:07 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 10,000 $0.00 Strike: $12.07 $0.00
Disclosure

SEC source: 0001415889-24-001520 · form4-01182024_090126.xml · derivative · entry 5

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 34,885

Underlying: Common Stock · 10,000 shares

Expires 2027-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F3 · derivative.exercise_date: This option was granted on February 22, 2017 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
January 16, 2024 Filed Jan 18, 2024 21:07 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 10,000 $36.00 $360,000.00
Disclosure

SEC source: 0001415889-24-001520 · form4-01182024_090126.xml · nonDerivative · entry 2

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 151,911

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

Read SEC document
January 16, 2024 Filed Jan 18, 2024 21:07 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 10,000 $12.07 $120,700.00
Disclosure

SEC source: 0001415889-24-001520 · form4-01182024_090126.xml · nonDerivative · entry 1

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 161,911

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

Read SEC document
December 13, 2023 Filed Dec 14, 2023 00:48 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 10,000 $0.00 Strike: $12.07 $0.00
Disclosure

SEC source: 0001415889-23-016423 · form4-12142023_121225.xml · derivative · entry 9

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,885

Underlying: Common Stock · 10,000 shares

Expires 2027-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F6 · derivative.exercise_date: This option was granted on February 22, 2017 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
December 13, 2023 Filed Dec 14, 2023 00:48 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 10,000 $40.39 $403,940.00
Disclosure

SEC source: 0001415889-23-016423 · form4-12142023_121225.xml · nonDerivative · entry 6

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 151,911

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F4 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $40.20 to $40.72. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
December 13, 2023 Filed Dec 14, 2023 00:48 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 10,000 $12.07 $120,700.00
Disclosure

SEC source: 0001415889-23-016423 · form4-12142023_121225.xml · nonDerivative · entry 5

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 161,911

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

Read SEC document
December 12, 2023 Filed Dec 14, 2023 00:48 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 1,467 $0.00 Strike: $12.07 $0.00
Disclosure

SEC source: 0001415889-23-016423 · form4-12142023_121225.xml · derivative · entry 8

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,885

Underlying: Common Stock · 1,467 shares

Expires 2027-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F6 · derivative.exercise_date: This option was granted on February 22, 2017 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
December 12, 2023 Filed Dec 14, 2023 00:48 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 8,533 $0.00 Strike: $13.81 $0.00
Disclosure

SEC source: 0001415889-23-016423 · form4-12142023_121225.xml · derivative · entry 7

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,533 shares

Expires 2025-02-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F5 · derivative.exercise_date: This option was granted on February 4, 2015 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
December 12, 2023 Filed Dec 14, 2023 00:48 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 643 $40.47 $26,019.00
Disclosure

SEC source: 0001415889-23-016423 · form4-12142023_121225.xml · nonDerivative · entry 4

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 151,911

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $39.25 to $40.19. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $40.315 to $40.50. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
December 12, 2023 Filed Dec 14, 2023 00:48 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 9,357 $39.58 $370,303.28
Disclosure

SEC source: 0001415889-23-016423 · form4-12142023_121225.xml · nonDerivative · entry 3

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 152,554

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $39.25 to $40.19. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
December 12, 2023 Filed Dec 14, 2023 00:48 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 1,467 $12.07 $17,706.69
Disclosure

SEC source: 0001415889-23-016423 · form4-12142023_121225.xml · nonDerivative · entry 2

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 161,911

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

Read SEC document
December 12, 2023 Filed Dec 14, 2023 00:48 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 8,533 $13.81 $117,840.73
Disclosure

SEC source: 0001415889-23-016423 · form4-12142023_121225.xml · nonDerivative · entry 1

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 160,444

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

Read SEC document
November 15, 2023 Filed Nov 16, 2023 21:18 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 10,000 $0.00 Strike: $13.81 $0.00
Disclosure

SEC source: 0001415889-23-015195 · form4-11162023_091135.xml · derivative · entry 9

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,533

Underlying: Common Stock · 10,000 shares

Expires 2025-02-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F4 · derivative.exercise_date: This option was granted on February 4, 2015 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
November 15, 2023 Filed Nov 16, 2023 21:18 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 10,000 $39.79 $397,880.00
Disclosure

SEC source: 0001415889-23-015195 · form4-11162023_091135.xml · nonDerivative · entry 6

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 151,911

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $39.335 to $40.155. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
November 15, 2023 Filed Nov 16, 2023 21:18 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 10,000 $13.81 $138,100.00
Disclosure

SEC source: 0001415889-23-015195 · form4-11162023_091135.xml · nonDerivative · entry 5

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 161,911

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

Read SEC document
November 14, 2023 Filed Nov 16, 2023 21:18 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 1,708 $0.00 Strike: $16.78 $0.00
Disclosure

SEC source: 0001415889-23-015195 · form4-11162023_091135.xml · derivative · entry 8

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 292

Underlying: Common Stock · 1,708 shares

Expires 2028-07-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F5 · derivative.exercise_date: This option was granted on July 2, 2018 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
November 14, 2023 Filed Nov 16, 2023 21:18 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 8,292 $0.00 Strike: $13.81 $0.00
Disclosure

SEC source: 0001415889-23-015195 · form4-11162023_091135.xml · derivative · entry 7

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,533

Underlying: Common Stock · 8,292 shares

Expires 2025-02-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F4 · derivative.exercise_date: This option was granted on February 4, 2015 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
November 14, 2023 Filed Nov 16, 2023 21:18 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 1,708 $39.08 $66,746.93
Disclosure

SEC source: 0001415889-23-015195 · form4-11162023_091135.xml · nonDerivative · entry 4

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 151,911

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $38.75 to $39.62. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
November 14, 2023 Filed Nov 16, 2023 21:18 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 1,708 $16.78 $28,660.24
Disclosure

SEC source: 0001415889-23-015195 · form4-11162023_091135.xml · nonDerivative · entry 3

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 153,619

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

Read SEC document
November 14, 2023 Filed Nov 16, 2023 21:18 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 8,292 $39.08 $324,043.07
Disclosure

SEC source: 0001415889-23-015195 · form4-11162023_091135.xml · nonDerivative · entry 2

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 151,911

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $38.75 to $39.62. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
November 14, 2023 Filed Nov 16, 2023 21:18 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 8,292 $13.81 $114,512.52
Disclosure

SEC source: 0001415889-23-015195 · form4-11162023_091135.xml · nonDerivative · entry 1

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 160,203

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

Read SEC document
October 17, 2023 Filed Oct 17, 2023 23:28 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 10,000 $0.00 Strike: $19.98 $0.00
Disclosure

SEC source: 0001415889-23-014366 · form4-10172023_111007.xml · derivative · entry 3

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 41,099

Underlying: Common Stock · 10,000 shares

Expires 2030-02-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sale reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2022.

F2 · derivative.exercise_date: This option was granted on February 10, 2020 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
October 17, 2023 Filed Oct 17, 2023 23:28 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 10,000 $36.52 $365,200.00
Disclosure

SEC source: 0001415889-23-014366 · form4-10172023_111007.xml · nonDerivative · entry 2

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 151,911

F1 · kind: The option exercise and sale reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2022.

Read SEC document
October 17, 2023 Filed Oct 17, 2023 23:28 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 10,000 $19.98 $199,800.00
Disclosure

SEC source: 0001415889-23-014366 · form4-10172023_111007.xml · nonDerivative · entry 1

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 161,911

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sale reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2022.

Read SEC document
September 19, 2023 Filed Sep 19, 2023 20:09 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 10,000 $0.00 Strike: $19.98 $0.00
Disclosure

SEC source: 0001415889-23-013397 · form4-09192023_080951.xml · derivative · entry 3

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,099

Underlying: Common Stock · 10,000 shares

Expires 2030-02-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2022.

F3 · derivative.exercise_date: This option was granted on February 10, 2020 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
September 19, 2023 Filed Sep 19, 2023 20:09 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 10,000 $39.10 $390,980.00
Disclosure

SEC source: 0001415889-23-013397 · form4-09192023_080951.xml · nonDerivative · entry 2

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 151,911

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2022.

F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $38.885 to $39.29. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
September 19, 2023 Filed Sep 19, 2023 20:09 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 10,000 $19.98 $199,800.00
Disclosure

SEC source: 0001415889-23-013397 · form4-09192023_080951.xml · nonDerivative · entry 1

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 161,911

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2022.

Read SEC document
August 22, 2023 Filed Aug 23, 2023 21:08 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 8,075 $0.00 Strike: $19.98 $0.00
Disclosure

SEC source: 0001415889-23-012570 · form4-08232023_090830.xml · derivative · entry 6

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 61,099

Underlying: Common Stock · 8,075 shares

Expires 2030-02-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person.

F4 · derivative.exercise_date: This option was granted on February 10, 2020 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
August 22, 2023 Filed Aug 23, 2023 21:08 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 1,925 $0.00 Strike: $18.41 $0.00
Disclosure

SEC source: 0001415889-23-012570 · form4-08232023_090830.xml · derivative · entry 5

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,580

Underlying: Common Stock · 1,925 shares

Expires 2028-02-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person.

F3 · derivative.exercise_date: This option was granted on February 14, 2018 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
August 22, 2023 Filed Aug 23, 2023 21:08 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 8,075 $42.41 $342,436.53
Disclosure

SEC source: 0001415889-23-012570 · form4-08232023_090830.xml · nonDerivative · entry 4

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 151,911

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $42.15 to $42.735. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
August 22, 2023 Filed Aug 23, 2023 21:08 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 8,075 $19.98 $161,338.50
Disclosure

SEC source: 0001415889-23-012570 · form4-08232023_090830.xml · nonDerivative · entry 3

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 159,986

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person.

Read SEC document
August 22, 2023 Filed Aug 23, 2023 21:08 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 1,925 $42.41 $81,633.48
Disclosure

SEC source: 0001415889-23-012570 · form4-08232023_090830.xml · nonDerivative · entry 2

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 151,911

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $42.15 to $42.735. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
August 22, 2023 Filed Aug 23, 2023 21:08 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 1,925 $18.41 $35,439.25
Disclosure

SEC source: 0001415889-23-012570 · form4-08232023_090830.xml · nonDerivative · entry 1

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 153,836

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person.

Read SEC document
July 18, 2023 Filed Jul 19, 2023 20:10 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 2,825 $0.00 Strike: $8.11 $0.00
Disclosure

SEC source: 0001415889-23-011318 · form4-07192023_080758.xml · derivative · entry 7

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 75,627

Underlying: Common Stock · 2,825 shares

Expires 2026-02-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
July 18, 2023 Filed Jul 19, 2023 20:10 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 7,175 $0.00 Strike: $13.81 $0.00
Disclosure

SEC source: 0001415889-23-011318 · form4-07192023_080758.xml · derivative · entry 6

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,825

Underlying: Common Stock · 7,175 shares

Expires 2025-02-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: This option was granted on February 4, 2015 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
July 18, 2023 Filed Jul 19, 2023 20:10 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 10,000 $0.00 Strike: $18.41 $0.00
Disclosure

SEC source: 0001415889-23-011318 · form4-07192023_080758.xml · derivative · entry 5

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,505

Underlying: Common Stock · 10,000 shares

Expires 2028-02-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercise and sale reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person.

F5 · derivative.exercise_date: This option was granted on February 14, 2018 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.